Tamiflu (Oseltamivir Phosphate) Market, by Drug Type (Branded and Generic), by Dosage Form (Capsules and Suspension), by Indication (Influenza A, Influenza B, and Swine Flu (H1N1 Influenza A)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jan 2023

Code : CMI5489

Pages :180

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

Global Tamiflu (Oseltamivir Phosphate) Market– Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic is expected to hamper the growth of the global Tamiflu (oseltamivir phosphate) market owning to the lockdown during COVID-19 pandemic. The coronavirus (COVID-19) pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors. The private healthcare sector is one of the sectors, which has been majorly impacted by the COVID-19 pandemic. The lockdown in various countries due to the COVID-19 pandemic has created an economic burden on the private healthcare sector. According to the Indian Journal of Medical Sciences published a report in 2020, the COVID-19 pandemic has affected the conduction of clinical trials due to the unavailability of trial site staff, restrictions for traveling, investigational product availability, and others.

According to National Center for Biotechnology Information (NCBI) published a report on April 29, 2020, many clinical trials suspended trial enrollment to minimize the risk of contracting COVID-19, and this has led to the delay in the activation of new clinical trials. Moreover, many companies have already missed the follow-up for the patients already in trials. Product development has experienced disruption to adjust to remote-work environments and lab capacity is reduced. Clinical trials are also being severely affected by disruptions in both new enrollments and in keeping existing patients on therapies. According to clinicaltrial.gov, as of April 2020, there were more than 2,850 trials and around 900,000 patients enrolled at trial sites in regions that were in partial or complete lockdown due to COVID-19 restrictions. While the R&D labs are currently operating at below 50% of the normal capacity across the globe. Many research centers have decided to freeze new trials and have stopped inpatient studies. Different pharmaceutical companies have also decided to delay the start of new clinical trials, suspended enrollment in some trials, and have postponed the initiation of new sites in the case of trials continuing enrollment.

Global Tamiflu (Oseltamivir Phosphate) Market: Restraint

The side effects of Tamiflu (oseltamivir phosphate)

The major factors that can hamper growth of the global Tamiflu (oseltamivir phosphate) market over the forecast period include product recall, product side effects and others. For instance, in 2021, Lupin Pharmaceuticals Inc, a pharmaceutical company, recalled a single lot of oseltamivir phosphate for oral suspension. The recall was initiated after the U.S. FDA enforcement report, when impurity was detected in the oral suspension.

Restaints